On April 28, 2026 the Jeffrey Modell Foundation (JMF) will host Luigi D. Notarangelo, M.D., the Chief of the Immune Deficiency Genetics Section at the National Institute of Allergy and Infectious ...

EMA’s panel backs a targeted therapy, which reduces lymphadenopathy and restores B-cell populations in patients with activated phosphoinositide 3-kinase delta syndrome.

If approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with primary immunodeficiencies demonstrated ...

Over one fourth of patients with common variable immunodeficiency have allergic diseases, with immunoglobulin E levels linked ...

Immunodeficiency diseases have traditionally been defined as defects in the development and function of T and B cells, the primary effector cells of specific cellular and humoral immunity respectively ...

Please provide your email address to receive an email when new articles are posted on . Ocular manifestations appeared common among patients with primary immunodeficiency diseases, suggesting a need ...

This grant builds upon Tessera’s existing investment from the Gates Foundation to develop a curative in vivo genetic ...

Scientists have long queried the causes of immune disorders in only one of two identical twins with identical genes. New research from the Wellcome Sanger Institute, the Josep Carreras Leukaemia ...

Mycobacterial diseases, most notably tuberculosis and infections from environmental mycobacteria, represent a significant global health challenge. Their clinical severity is often exacerbated in ...

A new immunodeficiency disease caused by a novel genetic mutation has been identified by researchers, providing unique insights into cell biology. A new immunodeficiency disease caused by a novel ...